Startup Rise EU News’ Post

It’s time to find out who bagged the biggest private biotech investments in June 2024! 💰 The biggest funding rounds went to the companies Formation Bio, ITM Isotope Technologies Munich SE, and Marea Therapeutics. 📈 Meanwhile, around the world, oncology and central nervous system players attracted the biggest funding rounds overall. 🌍 Read our latest article to find out more about biotech’s biggest private investments in June, as we break down the investments by location and funding type, and compare June’s fundraising to previous months. 💡 https://lnkd.in/dYvuBVt9 #biotechinvestments #oncologyresearch #biotechfunding #healthcareinnovation #investmenttrends #globalbiotech #lifesciences Santa Ana Bio, Inc. | Alzheon, Inc. | Preserving Future Memories | Bright Peak Therapeutics | iOnctura | InduPro | Exsilio Therapeutics | Elion Therapeutics | Enveda Biosciences | Iambic Therapeutics | Spur Therapeutics | āshibio, Inc | Adcytherix | Envisagenics | Vilya | Frontier Medicines | Augustine Therapeutics | GPN Vaccines

#fundingalert 💼Company: Pathios Therapeutics 💰Funding: €23.4 Million ⚡Round: Series B  👥Investors: Bristol Myers Squibb, Canaan and Brandon Capital. Launched in 2017, Pathios is a drug discovery and development company focused on translating innovative science into new medicines. Pathios was founded by a team of experienced biotech and pharmaceutical industry professionals, entrepreneurs, and clinicians. Proceeds from the raise will be used to support the continued development of Pathios’ unique approach to cancer immunotherapy focused on the inhibition of GPR65, a novel target that has been genetically associated with a range of immunologically-mediated diseases. Tom McCarthy, Stuart Hughes, Shelley Cook, David Miller, Barbara Cipriani, Anthony J. Good, PhD Read more - https://lnkd.in/gGQbUjbg To share your startup story write us on - contact@startuprise.co.uk #Pathios #development #innovative #medtech #immunotherapy #biotech #pharmaceutical #funding #fundingnews #startupnews #news #startuprise

🌟 Capstan Therapeutics Secures $175M in Oversubscribed Series B Financing 🌟 In an impressive development, Capstan Therapeutics has successfully closed a remarkable $175 million in oversubscribed Series B financing. This strategic round was led by RA Capital Management and saw participation from a host of new investors including Forbion, Johnson & Johnson Innovation – JJDC, Mubadala Capital, Perceptive Advisors, and Sofinnova Investments. This influx of support also included continued investments from Capstan’s stalwart existing backers. The funds from this financing round are earmarked for a pivotal advancement: propelling Capstan’s flagship in vivo CAR-T product candidate, CPTX2309, towards early clinical proof-of-concept in autoimmune disorders. CPTX2309, leveraging Capstan’s innovative tLNP platform, aims to revolutionize the treatment landscape by enabling the in vivo engineering of CAR-T cells, offering a potential leap forward in autoimmune therapy. With this funding, Capstan also welcomes Nanna Luneborg, Ph.D., MBA, a General Partner at Forbion, to its Board of Directors, marking a significant addition to its leadership team as the company navigates through this critical phase. This series B financing not only underscores the confidence in Capstan’s pioneering in vivoCAR-T technology but also highlights the collective vision of an exceptional syndicate of investors. Their backing is instrumental as Capstan embarks on its mission to bring novel therapeutic modalities to patients, underscoring a shared commitment to transforming patient care through innovation. #CapstanTherapeutics #BiotechInnovation #SeriesBFinancing #HealthcareInvestment

Buy vs R&D: the Pharma version of Open Innovation Pharmaceutical companies look to VC startup portfolios for M&A.   Amgen, Mayo Clinic and AbbVie are set to notch up an exit after fellow investor Merck agreed to buy neurodegenerative disease drug developer Caraway Therapeutics, Inc. for up to $610m, a handy return for a company that had only revealed $23m in funding.  The deal came the same week as Boehringer Ingelheim agreed a $490m purchase of one of its portfolio companies, cancer therapy developer T3 Pharma. As the IPO market continues to stagnate, we might see more deals where pharma firms explore VC and CVC portfolios for acquisitions rather than just backing another funding round. #VC #startup #scaleup #openinnovation #pharma Mind the Bridge

Biopharma Funding Activity May 20th-24th ‘24 2 newly launched companies and more funding events… Get these weekly → https://lnkd.in/gDdkUYb3 – 𝐏𝐫𝐢𝐯𝐚𝐭𝐞 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 – AltruBio Inc. 💸  Received an oversubscribed Series B financing of up to $225M led by BVF Partners LP, and other investors to support ongoing and planned Phase 2a and 2b clinical trials of immune checkpoint enhancer, ALTB-268, in ulcerative colitis. Pheon Therapeutics 💸  Completed a $120m Series B financing led by TCGX, with participation from BVF Partners and other investors. The funding will be used to further advance Pheon's differentiated ADC pipeline through clinical proof of concept for its first three assets in a wide range of solid tumors. SixPeaks Bio 💸  Launched with $110M funding: $30M in Series A led by Versant Ventures and $80M  non-dilutive financing from AstraZeneca. 𝐏𝐫𝐨𝐠𝐞𝐧𝐭𝐨𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 💸  Launched with $65M Series A financing led by Forbion to advance its multiple sclerosis program. Aktis Oncology 💸  Received $60M upfront cash payment for the collaboration in addition to an equity investment in Aktis by Lilly to generate novel tumor-targeting radiopharmaceuticals. – 𝐏𝐨𝐬𝐭-𝐈𝐏𝐎/𝐏𝐮𝐛𝐥𝐢𝐜 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 – Bicycle Therapeutics 🏦  Announced $555M private investment in public equity. Cytokinetics 🏦  Announced pricing of $500M stock offering. Dyne Therapeutics 🏦  Announced pricing of $325.5M public offering. Erasca, Inc.  🏦  Announced closing of $184M offering. Foghorn Therapeutics Inc. 🏦  Announced pricing of $110M direct offering and pre-funded warrants. --- 👋 I'm Dominic Vacchiano, Co-founder of BiopharmIQ by Amp. We provide biopharma data to help with your sales/BD activities. 📰 Each week we share clinical/regulatory/funding news in an easy-to-digest format. #biotech #biopharma

🚀 Exciting News from Avalo Therapeutics, Inc. (Nasdaq: AVTX) 🚀   #Avalo is investing over $22 million in stock and cash to acquire #AlmataBio for the anti-IL-1β monoclonal antibody AVTX-009, which originated from Eli Lilly.   AVTX-009 is considered a significant asset by Avalo, with the belief that it has the potential to be a leading treatment for hidradenitis suppurativa (HS) due to its target specificity, half-life, and potency. The company views HS as a lucrative commercial opportunity and aims for AVTX-009 to be best-in-class and best-in-indication, offering strong efficacy and convenient dosing.   Avalo's focus remains on developing AVTX-009 for HS, with topline results from a planned Phase 2 trial expected in 2026. Stay tuned for updates as Avalo continues its mission to revolutionize treatment for inflammatory diseases! 💊✨ #AvaloTherapeutics #Innovation #Biotech #HealthcareInvestment   Detailed News: https://lnkd.in/dKeTcDXK

The IL-1 story is not new. It was first described in 1940s, albeit with a different name pyrexin. With the advent of new nomenclature in the 70s, the term IL-1 was used to unite a range of immune artifacts. Since then a lot of research has been done on IL-1 and its role in #inflammatorydisorders. However, only three products can truly claim success - #anakinra, #canakinumab and #rilonacept. For the longest time, IL-1 story was like that of Heat Shock Protein OR Natural Killer Cell Story - it just refused to die! That is...till now. Thanks to the persistence of researchers, we now have a "blooming" pipeline of IL-targeting pharmaceuticals being studied across various inflammatory diseases. For a disease with a global prevalence of <1%, hidradenitis suppurativa (HS) certainly has attracted a lot of attention in the recent years - There are more than a dozen pharmacological agents in development with leading Big Pharm companies such as #Novartis, #UCB, #Sanofi, #Boehringer and #Abbvie leading the IL-1 targeting drug development landscape. At #ralss, we whole-heartedly support #biotechstartups who aspire to compete with the big companies. We anticipate that HS will very rapidly become a complex market for entrants such as #avalotherapeutics Will they develop their newly acquired AVTX-009 all the way to market OR do they aspire to exit (via molecule/company acquisition)? Only time will tell. Regardless of #competitiveintensity and #marketcomplexity, HS patients can anticipate a range of treatment options coming their way. 

Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio. Here are some key points to note summarized below: 1. Avalo entered into a definitive agreement for the sale of preferred stock and warrants in a private placement. The private placement will provide up to $185 million in gross proceeds, including an initial gross upfront investment of $115.6 million 2. Avalo intends to pursue the development of AVTX-009 in hidradenitis suppurativa 3. Topline results from a planned Phase 2 trial in HS are expected in 2026 and the upfront funding is expected to fund operations through this data readout and into 2027 4. In addition to HS, Avalo intends to develop AVTX-009 in at least one other chronic inflammatory indication Read the articlefor further details!! #raslss #industrynews #pharmanews #pharmaindustry #acquisition #M&A #pharmadeals

🚀🔬 It’s time to take a look at the biggest private biotech investments of July 2024! 💰 Last month, the companies Cardurion Pharmaceuticals, Beacon Therapeutics, and Third Arc Bio bagged the biggest investment rounds. 🎯 And, just as in June, oncology and central nervous system players attracted the biggest funding rounds overall. 🧠💉 📍Plus, in terms of location, North America and Europe also achieved the same amount of fundraising rounds as they did in June, with 15 and 11 respectively. 🌍💼 Read our latest article to find out more details! 🔍 https://lnkd.in/d4xze2x7 #biotech #investments #pharma #oncology #innovation #funding #biotech2024 #healthcare CatalYm GmbH | Scorpion Therapeutics | NGM Biopharmaceuticals | Myricx Bio | Asceneuron SA | Autobahn Therapeutics, Inc. | SciRhom | Confo Therapeutics | GRO Biosciences | AIRNA | SmartCella Holding AB | AusperBio | Rona Therapeutics | CellCentric | ReviR Therapeutics | LTZ Therapeutics

Alumis, an 𝐢𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐲 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 on the cusp of 𝐏𝐡𝐚𝐬𝐞 𝟑, has secured $𝟐𝟓𝟎𝐌 𝐢𝐧 𝐚 𝐬𝐡𝐫𝐮𝐧𝐤𝐞𝐧 𝐈𝐏𝐎. The Bay Area startup sold 𝟏𝟑.𝟏𝟐 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐬𝐡𝐚𝐫𝐞𝐬 𝐚𝐭 $𝟏𝟔 𝐞𝐚𝐜𝐡 to fund the late-stage testing of its lead 𝐓𝐘𝐊𝟐 𝐝𝐫𝐮𝐠, studies of a second asset in neuroinflammatory conditions, and preclinical projects. While the IPO was smaller than initially projected, an additional 𝟐.𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐬𝐡𝐚𝐫𝐞𝐬 were sold in a concurrent private placement. With $𝟑𝟒𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐚𝐥𝐥𝐨𝐜𝐚𝐭𝐞𝐝 toward clinical development, Alumis aims to create a next-gen immunology treatment, facing competition from Bristol Myers Squibb’s Sotyktu and Takeda’s TAK-279. Alumis has spent heavily on R&D, with $𝟏𝟑𝟕 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐥𝐚𝐬𝐭 𝐲𝐞𝐚𝐫 𝐚𝐧𝐝 $𝟏𝟎𝟏 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟐. The company, led by Martin Babler, hopes to buck the trend of biotechs trading below their IPO price. https://lnkd.in/eK_H6kda #Biotech #Immunology #IPO #Pharma #HealthcareInnovation